Novacyt (ALNOV) - Total Assets
Based on the latest financial reports, Novacyt (ALNOV) holds total assets worth €62.92 Million EUR (≈ $73.56 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Novacyt's book value for net asset value and shareholders' equity analysis.
Novacyt - Total Assets Trend (2008–2024)
This chart illustrates how Novacyt's total assets have evolved over time, based on quarterly financial data.
Novacyt - Asset Composition Analysis
Current Asset Composition (December 2024)
Novacyt's total assets of €62.92 Million consist of 55.8% current assets and 44.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €30.45 Million | 43.1% |
| Accounts Receivable | €3.71 Million | 5.3% |
| Inventory | €2.27 Million | 3.2% |
| Property, Plant & Equipment | €10.70 Million | 15.2% |
| Intangible Assets | €17.57 Million | 24.9% |
| Goodwill | €2.67 Million | 3.8% |
Asset Composition Trend (2008–2024)
This chart illustrates how Novacyt's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Novacyt market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novacyt's current assets represent 55.8% of total assets in 2024, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 43.1% of total assets in 2024, up from 0.9% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 12.0% in 2008.
- Asset Diversification: The largest asset category is cash and equivalents at 43.1% of total assets.
Novacyt Competitors by Total Assets
Key competitors of Novacyt based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Beijing Wandong Medical Technology Co Ltd
SHG:600055
|
China | CN¥5.70 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
MODULIGHT OY EO 1
F:78W
|
Germany | €49.14 Million |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Nova EYE Medical Ltd
AU:EYE
|
Australia | AU$23.67 Million |
Novacyt - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.03 | 4.04 | 2.41 |
| Quick Ratio | 4.59 | 3.82 | 1.83 |
| Cash Ratio | 3.54 | 2.42 | 0.00 |
| Working Capital | €27.00 Million | €41.38 Million | €34.69 Million |
Novacyt - Advanced Valuation Insights
This section examines the relationship between Novacyt's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.37 |
| Asset Growth Rate (YoY) | -47.2% |
| Total Assets | €70.63 Million |
| Market Capitalization | $26.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Novacyt's assets below their book value (0.37x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Novacyt's assets decreased by 47.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Novacyt (2008–2024)
The table below shows the annual total assets of Novacyt from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €70.63 Million ≈ $82.58 Million |
-47.22% |
| 2023-12-31 | €133.81 Million ≈ $156.44 Million |
-5.03% |
| 2022-12-31 | €140.90 Million ≈ $164.73 Million |
-23.30% |
| 2021-12-31 | €183.70 Million ≈ $214.76 Million |
-21.59% |
| 2020-12-31 | €234.28 Million ≈ $273.89 Million |
+782.73% |
| 2019-12-31 | €26.54 Million ≈ $31.03 Million |
-9.45% |
| 2018-12-31 | €29.31 Million ≈ $34.27 Million |
-2.96% |
| 2017-12-31 | €30.20 Million ≈ $35.31 Million |
+16.40% |
| 2016-12-31 | €25.95 Million ≈ $30.34 Million |
+105.56% |
| 2015-12-31 | €12.62 Million ≈ $14.76 Million |
-39.23% |
| 2014-12-31 | €20.77 Million ≈ $24.28 Million |
+680.10% |
| 2013-12-31 | €2.66 Million ≈ $3.11 Million |
-19.30% |
| 2012-12-31 | €3.30 Million ≈ $3.86 Million |
+162.00% |
| 2011-12-31 | €1.26 Million ≈ $1.47 Million |
-33.72% |
| 2010-12-31 | €1.90 Million ≈ $2.22 Million |
-0.94% |
| 2009-12-31 | €1.92 Million ≈ $2.24 Million |
+16.45% |
| 2008-12-31 | €1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more